



Company Profile

Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as the AC5 Surgical Hemostatic Device™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures and is intended to be regulated as a medical device.

Management Team

Dr. Terrence W. Norchi

President, Chief Executive Officer and Director

Richard E. Davis

Chief Financial Officer

Recent News

Thursday, December 20, 2018 - 07:50 AM

[Arch Therapeutics to Provide Corporate Update at the 11th Annual Biotech Showcase™ 2019 Conference on January 8th, 2019](#)

Monday, December 17, 2018 - 07:50 AM

[Arch Therapeutics Receives 510\(k\) Clearance from the US FDA for AC5™ Topical Gel](#)

Thursday, December 06, 2018 - 07:50 AM

[Arch Therapeutics Provided Corporate Update at the 11th Annual LD Micro Main Event](#)

Tuesday, December 04, 2018 - 07:50 AM

[Arch Therapeutics Announces Positive Outcome of Ruling from Japanese Intellectual Property High Court](#)

Wednesday, November 28, 2018 - 07:50 AM

[Arch Therapeutics Announces Submission of CE Mark File for AC5™ Topical Hemostat in Europe](#)

DISCLAIMER

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.

Contact Information

Arch Therapeutics, Inc.

235 Walnut Street
Suite 6
Framingham, MA 01702

OTCQB: ARTH



Share Price	\$0.43
Volume	231.62k
Shares Outstanding	164,441,786
Market Cap	\$70.3m
52 Week High	\$0.69
52 Week Low	\$0.26

as of 01/18/2019